|Articles|June 22, 2017
PAREXEL is Acquired by Pamplona Capital Management
Advertisement
PAREXEL International Corporation announced that Pamplona Capital Management, LLP has acquired all of its outstanding shares, including Parexel's net debt, for $88.10 per share in cash-valued at approximately $5 billion.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Two New Partnerships Aim to Expand Patient Access to Clinical Trials Through Community-Based Research
2
ACT Brief: Sponsor Oversight Capability Gaps, Community-Embedded Trial Partnerships, and Trialblazer Timeline Realism
3
ACT Brief: Product Development Assumptions, Portfolio-Level Recruitment Infrastructure, and Risk-Based Quality Integration
4
ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN
5